GenSpera Presents at Noble Financial Conference

SAN ANTONIO, Jan. 13, 2015 /PRNewswire/ -- GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today that Craig A. Dionne, Ph.D., chief executive officer at GenSpera, will present on Monday, January 19, at 12:30 pm EST at the Noble Financial Capital Markets' Eleventh Annual Equity Conference in Sandpiper Bay, Florida.

The presentation will follow GenSpera's participation in the 2015 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology held this week in San Francisco. During the symposium, GenSpera will present positive data from Phase II clinical trials of mipsagargin in patients with liver (hepatocellular carcinoma) cancer. 

"This is a promising time for GenSpera and the ongoing development of mipsagargin," said Dionne.  "With more than 90 percent of oncology agents failing in phase II trials, we are proud to have present positive data at ASCO GI and to be preparing to move forward with large, global phase III trials."

A live audio and high-definition video webcast of GenSpera's presentation and a copy of the presentation materials will be available on www.genspera.com, or through the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/D2/2015.htm. GenSpera recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will also be archived on www.genspera.com  for 90 days following the event.

About GenSpera

GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for the targeted release of drug candidates within tumors. GenSpera's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the US Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Cautionary Statement Regarding Forward Looking Information

This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera's technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera's proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

SOURCE GenSpera Inc.

Related Links

http://www.genspera.com